European Parliament tables ~3,000 amendments to biotech rules, sparking clash over pharma funding and incentives

Published Jul 20, 02:38 AM UTC

Lawmakers in the European Parliament have tabled approximately 3,000 amendments to the EU's new biotech rules, setting the stage for intense political clashes over pharmaceutical funding and incentives. The amendments reflect deep divisions among political groups regarding the regulation of biotechnology, including issues of intellectual property, pricing, and access to medicines. The debate centers on how to balance innovation incentives with public health needs and affordability. The outcome will shape the EU's biotech landscape and pharmaceutical industry for years to come.